Bio-Rad's Aspergillus EIA Test Kit Receives FDA 510(k) Clearance
HERCULES, Calif. -- Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research products and clinical diagnostics announced that on May 16 it received Food and Drug Administration (FDA) clearance to market its Platelia Aspergillus EIA test kit in the United States.
It is the first test available in the U.S. for Invasive Aspergillosis. Hospital laboratories, reference laboratories and transplant centers may now use the test as an aid in the diagnosis of the infection. The test has been used extensively in Europe and in a recent North American study, the test proved to be accurate in diagnosing the infection in bone marrow transplant and leukemia patients.
"We are very pleased to receive FDA clearance for this test," said John Goet, Bio-Rad vice president and group manager of clinical diagnostics. "We look forward to making it available for widespread use in the U.S. and hope that it will lead to faster, improved methods of treatment."
Invasive Aspergillosis is one of the most common opportunistic fungal infections and causes high mortality rates in immunocompromised patients like bone marrow transplant patients and patients with hematological malignancies. More than 17,000 bone marrow transplants are conducted each year in the U.S. Mortality rates for invasive Aspergillosis have been reported to be as high as 50-100 percent. The infection is typically very difficult to diagnose and traditional methods of diagnosis such as histopathological examination of biopsies and/or radiological examinations not only require invasive surgical procedures, but can also produce results that are inconclusive, often leading to inappropriate treatment and death. Bio-Rad's Aspergillus test is an accurate, non-invasive EBA-2 monoclonal antibody based microplate assay that utilizes blood samples for testing and can be used in conjunction with other diagnostic methods.
Bio-Rad Laboratories, Inc. is a multinational manufacturer and distributor of life science research products and clinical diagnostics.
Source: Bio-Rad Laboratories, Inc.
Genomic Surveillance A New Frontier in Health Care Outbreak Detection
November 27th 2024According to new research, genomic surveillance is transforming health care-associated infection detection by identifying outbreaks earlier, enabling faster interventions, improving patient outcomes, and reducing costs.
Point-of-Care Engagement in Long-Term Care Decreasing Infections
November 26th 2024Get Well’s digital patient engagement platform decreases hospital-acquired infection rates by 31%, improves patient education, and fosters involvement in personalized care plans through real-time interaction tools.
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
